KR-33028

KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke[1][2].

Product Specifications

CAS Number

[861218-37-3]

UNSPSC

12352005

Target

Apoptosis; Na+/H+ Exchanger (NHE)

Related Pathways

Apoptosis; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Smiles

O=C(C1=CC2=C(C#N)C=CC=C2S1)NC(N)=N

Molecular Formula

C11H8N4OS

Molecular Weight

244.27

References & Citations

[1]Amith SR, et al. KR-33028, a potent inhibitor of the Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells. Biochem Pharmacol. 2016 Oct 15;118:31-39.|[2]Jung YS, et al. Pharmacological profile of KR-33028, a highly selective inhibitor of Na+/H+ exchanger. Eur J Pharmacol. 2006 Mar 27;535 (1-3) :220-7.